Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1/2 2Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 12Neoplasm Metastasis 3Stomach Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms 1HER2-positive Gastric Cancer 1HER2-Positive Primary Breast Cancer 1Carcinoma, Ovarian Epithelial 1Breast Diseases 1Brain Neoplasms 1Biliary Tract Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1Adenocarcinoma 1

Interventions

Carboplatin 190Cisplatin 156Pemetrexed 151Paclitaxel 127Docetaxel 109pembrolizumab 87Gemcitabine 73Erlotinib Hydrochloride 44Radiotherapy 39Vinorelbine 35Gefitinib 34durvalumab 31Bevacizumab 28Nivolumab 26Drug Therapy 23atezolizumab 22osimertinib 19130-nm albumin-bound paclitaxel 19tislelizumab 16Crizotinib 16Radiosurgery 15Etoposide 14Surgical Procedures, Operative 11Afatinib 11Ipilimumab 10icotinib 9aumolertinib 9Albumin-Bound Paclitaxel 9Specimen Handling 8Observation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Non-Small-Cell Lung × trastuzumab deruxtecan × Clear all
NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

AstraZeneca

Phase 3 Active not recruiting
454 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06899126 2026-01-08

DESTINY-Lung06

Daiichi Sankyo

Phase 3 Recruiting
686 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡